Sun Pharma launches ready-to-infuse INFUGEM – the first and only chemotherapy product in a premixed, ready-to-infuse formulation – in the US.
Source: www.businesswire.com
Sun Pharmaceutical Industries Ltd. has announced the launched its INFUGEM injections (gemcitabine in sodium chloride injection) product. This premixed formulation is used by patients in the US market for the treatment of cancer. INFUGEM utilizies Sun Pharmaceutical’s proprietary technology which allows cytotoxic oncology products to be premixed in a sterile environment and supplied to the prescribers in ready-to-infuse final dosage bags. INFUGEM was first approved by the U.S. Food and Drug Administration in July 2018 in combination with other drugs for the treatment of breast, ovarian, non-small cell lung cancers, and as a single agent for the treatment of pancreatic cancer.
